Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Aug. 24, 2026—The Food and Drug Administration has cleared Roche’s Elecsys Phospho-Tau (217P) Plasma (pTau217) blood test, to aid in identifying amyloid pathology associated with Alzheimer’s disease in people 55 years and older with signs, symptoms, or complaints of cognitive decline.
Aug. 21, 2026—The Digital Pathology Association’s annual meeting, Pathology Visions 2026, is taking place October 16–18 in San Diego.
Aug. 20, 2026—The U.S. Food and Drug Administration authorized Vitestro’s Aletta, the first standalone robotic device that can draw blood from a patient’s arm without hands-on operator intervention.
Aug. 19, 2026—Pillar Biosciences, LC-SCRUM-Asia, and LSI Medience Corp. are collaborating to support the genomic screening of blood-based samples from patients with lung cancer as part of the LC-SCRUM-Asia project in Japan.
Aug. 12, 2026—Zepto Life Technology has been awarded a contract valued at up to $8.9 million from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, to advance the company’s plasma cell-free DNA liquid biopsy platform for invasive fungal infections.
Aug. 11, 2026—The FDA has cleared Qiagen’s QIAstat-Dx BCID GPF Plus AMR panel, the first QIAstat-Dx panel for bloodstream infections to receive FDA clearance.
Aug. 10, 2026—Proscia received a new FDA 510(k) clearance for the Concentriq AP-Dx, a digital pathology platform for primary diagnosis.
Aug. 7, 2026—Roche, in collaboration with subsidiary Tib Molbiol, released two research PCR testing options for labs to address the public health impact of the Cyclospora cayetanensis parasite.
Aug. 6, 2026—Epredia announced an agreement with Canada-based manufacturer Lab Improvements to bring automated archiving to U.S. pathology labs, adding Lab Improvements’ BlockTracker and SlideTracker to its product portfolio.
July 29, 2026–Roche received FDA 510(k) clearance for its Cobas BV/CV assay.
